ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 113 filers reported holding ALDEYRA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,517,627 | -18.5% | 975,572 | +2.3% | 0.00% | 0.0% |
| Q2 2023 | $7,997,770 | +64.9% | 953,250 | +95.2% | 0.00% | 0.0% |
| Q1 2023 | $4,849,269 | +149246.1% | 488,345 | +4.7% | 0.00% | – |
| Q4 2022 | $3,247 | -99.9% | 466,577 | -0.6% | 0.00% | – |
| Q3 2022 | $2,506,000 | +29.0% | 469,429 | -3.6% | 0.00% | – |
| Q2 2022 | $1,942,000 | -52.1% | 486,769 | -46.7% | 0.00% | -100.0% |
| Q1 2022 | $4,057,000 | +18.9% | 912,868 | +7.0% | 0.00% | – |
| Q4 2021 | $3,411,000 | -56.9% | 852,760 | -5.5% | 0.00% | -100.0% |
| Q3 2021 | $7,918,000 | -22.2% | 901,917 | +0.4% | 0.00% | 0.0% |
| Q2 2021 | $10,180,000 | +115.1% | 898,517 | +125.5% | 0.00% | 0.0% |
| Q1 2021 | $4,733,000 | +127.3% | 398,437 | +31.3% | 0.00% | – |
| Q4 2020 | $2,082,000 | +4.6% | 303,505 | +13.0% | 0.00% | – |
| Q3 2020 | $1,990,000 | +99.2% | 268,592 | +12.1% | 0.00% | – |
| Q2 2020 | $999,000 | +21.7% | 239,598 | -28.0% | 0.00% | – |
| Q1 2020 | $821,000 | -78.6% | 332,754 | -49.5% | 0.00% | – |
| Q4 2019 | $3,830,000 | +138.5% | 659,384 | +116.4% | 0.00% | – |
| Q3 2019 | $1,606,000 | -11.9% | 304,744 | +0.3% | 0.00% | – |
| Q2 2019 | $1,822,000 | -26.5% | 303,789 | +10.7% | 0.00% | -100.0% |
| Q1 2019 | $2,478,000 | -39.1% | 274,448 | -44.1% | 0.00% | 0.0% |
| Q4 2018 | $4,072,000 | +88.8% | 490,784 | +213.9% | 0.00% | 0.0% |
| Q3 2018 | $2,157,000 | +83.7% | 156,335 | +5.8% | 0.00% | – |
| Q2 2018 | $1,174,000 | +53.3% | 147,737 | +44.5% | 0.00% | – |
| Q1 2018 | $766,000 | +10.2% | 102,263 | 0.0% | 0.00% | – |
| Q4 2017 | $695,000 | +27.1% | 102,263 | +34.6% | 0.00% | – |
| Q3 2017 | $547,000 | +101.8% | 75,994 | +31.4% | 0.00% | – |
| Q2 2017 | $271,000 | -1.1% | 57,854 | +5.4% | 0.00% | – |
| Q1 2017 | $274,000 | -3.2% | 54,888 | +3.6% | 0.00% | – |
| Q4 2016 | $283,000 | -31.8% | 52,976 | 0.0% | 0.00% | – |
| Q3 2016 | $415,000 | +171.2% | 52,976 | +96.4% | 0.00% | – |
| Q2 2016 | $153,000 | +56.1% | 26,977 | +14.5% | 0.00% | – |
| Q1 2016 | $98,000 | -35.5% | 23,558 | +4.4% | 0.00% | – |
| Q4 2015 | $152,000 | +16.0% | 22,558 | 0.0% | 0.00% | – |
| Q3 2015 | $131,000 | -25.1% | 22,558 | 0.0% | 0.00% | – |
| Q2 2015 | $175,000 | -25.2% | 22,558 | 0.0% | 0.00% | – |
| Q1 2015 | $234,000 | +44.4% | 22,558 | 0.0% | 0.00% | – |
| Q4 2014 | $162,000 | +20.0% | 22,558 | 0.0% | 0.00% | – |
| Q3 2014 | $135,000 | – | 22,558 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 908,488 | $6,232,000 | 2.88% |
| Knoll Capital Management, LLC | 569,405 | $3,906,000 | 2.66% |
| Mesirow Financial Investment Management, Inc. | 64,698 | $443,828,000 | 1.40% |
| Ghost Tree Capital, LLC | 650,000 | $4,459,000 | 0.99% |
| Johnson & Johnson Innovation - JJDC, Inc. | 594,834 | $4,081,000 | 0.53% |
| Perceptive Advisors | 6,285,458 | $43,118,000 | 0.46% |
| Affinity Asset Advisors, LLC | 100,000 | $686,000 | 0.36% |
| ACUTA CAPITAL PARTNERS, LLC | 192,500 | $1,321,000 | 0.36% |
| Avidity Partners Management LP | 1,435,000 | $9,844,000 | 0.32% |
| APOGEM CAPITAL LLC | 55,821 | $383,000 | 0.26% |